corporate presentation - cryoport,...
TRANSCRIPT
Corporate Presentation
April 2016 1NASDAQ: CYRX
This presentation contains certain forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include statements regarding attempts to
identify new strategic opportunities which may include a strategic transaction, plans
regarding partnering activities, product pricing, financial forecasts. Such statements are
only predictions and the Company's actual results may differ materially from those
anticipated in these forward-looking statements. Factors that may cause such differences
include the risk that the Company may not be able to identify acceptable strategic
opportunities or conclude any strategic transaction which it does identify, the risk that
products that appeared promising in early use do not demonstrate the same utility in
larger-scale uses, the risks associated with the Company's reliance on outside financing to
meet its capital requirements, and the risks associated with the Company's reliance on
collaborative partners for shipping. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted, or quantified. Future events
and actual results could differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and uncertainties to which forward-
looking statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks. These factors and others are more fully
discussed in the Company's periodic reports and other filings with the Securities and
Exchange Commission.
safe harbor – forward looking statements
April 2016 2
vision
to be the most comprehensive, fully integrated,
commercially successful life sciences enabling company in
the world providing full support including logistics, storage,
information for science and regulatory compliance and
fulfillment
to be known for leadership and dependability
to be known for agility, reliability, innovation, and
excellence
April 2016 3
company highlights
undisputed leading provider of advanced cryogenic logistics solutions for
the life sciences industry, an addressable market of over $2.0 billion*
growing more than 14% per year
fully integrated with FedEx, DHL and UPS
Q3 FY 2016 revenue increased 58%
over 28,000 shipments through 90 countries
over 550 clients engage our solutions today; 98 new biopharma clients
were added during the first three quarters
supporting 64 clinical trials with 10 in Phase III, which represents
approximately 20% of all the Phase III clinical trials for regenerative
therapies – including 8 of the top 10 CAR T-cell therapies
*Cryoport estimate for 2015
April 2016 4
life sciences cryogenic logistics market
could
should
current
temperature
+2 to +8˚C
- 80˚C
- 150˚C
dry ice
cryogenic
secondary market($300M – $500M)**
primary market
(approx. $1.7B)**
cry
op
ort
al
so
ftw
are
cry
op
ort
sh
ipp
ers
glass point
total life sciences cold chain logistics
services
(approx. $10B)*
*iMarc Report Global Healthcare Cold Chain Logistics Market Report & Forecast (2012-
2017); extrapolated for 2015
**Cryoport estimate for 2015
solutions
April 2016 5
biopharma/regenerative medicine
Source: Alliance for Regenerative Medicine, January 2016
6April 2016 6
biopharma market
The total biologics market is estimated to be $289 billion today and
growing at 10.8% annually; by extrapolation, in 2025 the market will be an
$800 to $900 billion, which will accelerate the cryogenic market growth
April 2016 7
cryoport express® shippersvalidated. safe. effective. efficent.
Cryoport
Express
®
Shipper
novel liquid nitrogen dry vapor technologies
(lighter than LN2 and dry ice)
designed for fragile biologic transport
stable cryogenic temperature below -150˚C
(below the “glass point”)
10 day “dynamic” holding time without need
for intervention
international air transport association (IATA)
certified, non-hazardous and “green”
smart pak® condition monitoring system
which monitors internal and external
temperatures, humidity, openings, etc
April 2016 8
proprietary information technology
the cryoportalTM is a cloud-based operating
platform that accepts orders, prepares paperwork,
tracks and monitors each shipment’s movement,
and maintains integrity throughout the entire
logistics process
vital information - dashboards and analytics for
visibility, analysis and improved operations
regulatory information - provides chain-of-custody and
chain-of-condition
innovative – carrier agnostic software developed for life
sciences cold chain with time and temperature
sensitivity
reliable – real time alerts and updates
cost effective – enables life sciences organizations to
manage their entire cold chain shipping process
April 2016 9
smart pak II® condition monitoring system chain-of-custody and chain-of-condition at your fingertips
10
real time tracking of key information – in beta testing
April 2016
global logistics expertise for life sciences
now serving over 90 countries, with recent expansion to Africa
global reach through cryoport’s operations centers in strategic locations
24/7/365 “live” logistics support
in compliance with regulations for the life sciences logistics space
enables customers to focus on their key competencies without the
concern of complicated logistics
Irvine, CA
11
strategic alliances:
April 2016 12
Renewed Dec 2015
CAR-T cell therapy logistics
demand is projected to ramp
significantly starting in late 2017,
2018
Cryoport is being requested to
support demand in the 100,000’s of
units a year required for a single
therapy (multiple examples).
Our data is consistent with this data
from GE, we project volumes in
excess of 1,000,000 by 2019
car t-cell immunotherapy – scale-out needs
April 2016 13
Source: Presentation by Clive Glover, GE Healthcare, May 2015
clinical trials supported by cryoport
44%
35%
21%
Clinical Trials by Phase
Phase I
Phase II
Phase III
0
10
20
30
40
50
60
Clinical Trials Initiated by Year and Cumulative
April 2016 14
15
revenue growth
April 2016
CAGR of 83% over last 3 years
broad customer base
+ 53% + 74%
+ 44%
+ 50%
board of directors & management
board of directors
Jerrell Shelton, Chairman/CEO
Richard Berman, Lead Director, Chairman of Audit and Compensation
Committees
Robert Hariri, PhD, MD, Director
Ramkumar Mandalam, Ph.D., Director
Edward Zecchini, Chairman of the Nominating and Governance Committee
management
Robert Stefanovich, Chief Financial Officer
Mark W. Sawicki, Ph.D., Chief Commercial Officer
Tamie Joeckel, Senior Vice President, Client Services
Bret Bollinger, Vice President Operations
Thomas Heinzen, Vice President Corporate Development
April 2016 16
strong market positioning
April 2016 17
growing $2.0B addressable market
over $150 million of embedded growth residing in current
trials supported
commitments from FedEx, UPS, and DHL to employ
“powered by cryoport”
increasing regulatory requirements
sustainable first-to-market advantage with array of
advanced logistics solutions
over 550 clients; including 98 new biopharma clients added
in first 3 quarters
advanced technology, reliable, easy, “green”,
patent-protected, and validated frozen shipping solutions
Science. Logistics. Certainty.
NASDAQ: CYRX 18